The U.S. Food and Drug Administration on Friday approved vepdegestrant, a breast cancer therapy developed by Pfizer (PFE) and Arvinas (ARVN) under the brand name Veppanu. Accordingly, the once-daily ...
Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...
Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to ...
The FDA has approved Pfizer and Arvinas’ Veppanu, the first proteolysis-targeting chimera (PROTAC) therapy, for advanced ER-positive, HER2-negative breast cancer with ESR1 mutations after prior ...
Now, it’s worth noting Stock Advisor’s total average return is 968 % — a market-crushing outperformance compared to 202% for ...
Pharmaceutical Technology on MSN
Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy
Under the Prescription Drug User Fee Act, the FDA has set a target action date of 17 August 2026.
The pharmaceutical giant just extended the lifespan of one of its top drugs.
Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results